Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Amylyx Pharmaceuticals (AMLX) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • Amylyx Pharmaceuticals' Gains from Sales and Divestitures rose 6834.52% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 6834.52%. This contributed to the annual value of $712218.0 for FY2024, which is 28488.91% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $1.2 million for Q3 2025, which was up 6834.52% from $775162.0 recorded in Q2 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Gains from Sales and Divestitures peaked at $1.2 million during Q3 2025, and registered a low of $146694.0 during Q1 2023.
  • In the last 3 years, Amylyx Pharmaceuticals' Gains from Sales and Divestitures had a median value of $263901.0 in 2024 and averaged $473299.5.
  • Examining YoY changes over the last 5 years, Amylyx Pharmaceuticals' Gains from Sales and Divestitures showed a top increase of 30616.46% in 2024 and a maximum decrease of 5776.86% in 2024.
  • Amylyx Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $185045.0 in 2023, then soared by 284.89% to $712218.0 in 2024, then surged by 63.49% to $1.2 million in 2025.
  • Its Gains from Sales and Divestitures was $1.2 million in Q3 2025, compared to $775162.0 in Q2 2025 and $700488.0 in Q1 2025.